HUP0301830A3 - Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
HUP0301830A3
HUP0301830A3 HU0301830A HUP0301830A HUP0301830A3 HU P0301830 A3 HUP0301830 A3 HU P0301830A3 HU 0301830 A HU0301830 A HU 0301830A HU P0301830 A HUP0301830 A HU P0301830A HU P0301830 A3 HUP0301830 A3 HU P0301830A3
Authority
HU
Hungary
Prior art keywords
diabetes
treatment
combination
pharmaceutical composition
composition containing
Prior art date
Application number
HU0301830A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Metabasis Therapeutics Inc
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Sankyo Co filed Critical Metabasis Therapeutics Inc
Publication of HUP0301830A2 publication Critical patent/HUP0301830A2/hu
Publication of HUP0301830A3 publication Critical patent/HUP0301830A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0301830A 2000-07-06 2001-07-05 Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes HUP0301830A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
HUP0301830A2 HUP0301830A2 (hu) 2003-11-28
HUP0301830A3 true HUP0301830A3 (en) 2007-10-29

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301830A HUP0301830A3 (en) 2000-07-06 2001-07-05 Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
CA2343027A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ATE350385T1 (de) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc Neue aryl fructose-1,6-bisphosphatase inhibitoren
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
SI3002283T1 (en) 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
EP1857118A1 (en) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5086190A (en) * 1989-01-24 1990-09-05 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6691498A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
CA2343027A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
CA2673615C (en) * 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
RU2328308C2 (ru) 2008-07-10
WO2002003978A2 (en) 2002-01-17
PL365779A1 (en) 2005-01-10
AU2001273271B2 (en) 2006-01-05
WO2002003978A3 (en) 2003-10-16
IL153513A0 (en) 2003-07-06
KR100854851B1 (ko) 2008-08-27
IL153513A (en) 2014-07-31
JP2004508297A (ja) 2004-03-18
NO20030034D0 (no) 2003-01-03
BR0112212A (pt) 2003-12-30
CA2412142A1 (en) 2002-01-17
AU7327101A (en) 2002-01-21
EP1372660A2 (en) 2004-01-02
CZ20035A3 (cs) 2003-05-14
CN101301294A (zh) 2008-11-12
ZA200300044B (en) 2004-05-06
NZ523227A (en) 2005-04-29
SK62003A3 (en) 2003-09-11
MXPA02012713A (es) 2004-09-10
CN100396283C (zh) 2008-06-25
HUP0301830A2 (hu) 2003-11-28
KR20030031952A (ko) 2003-04-23
NO20030034L (no) 2003-03-05
CN1599612A (zh) 2005-03-23

Similar Documents

Publication Publication Date Title
HUP0301830A3 (en) Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
EP1389621A4 (en) N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
HUP0203965A3 (en) Indazole compounds and pharmaceutical compositions containing them
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0203700A3 (en) N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents and pharmaceutical compositions containing them
HUP0200831A3 (en) Novel pharmaceutical composition containing amoxycillin and its use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL148517A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL150077A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL143841A0 (en) Amide compounds and pharmaceutical compositions containing the same
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL149883A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP0204069A3 (en) Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0302397A3 (en) Heterocyclic compounds and pharmaceutical compositions containing them
EP1541139A4 (en) DRUG COMPOSITION WITH NF-KAPPA B HEMMER

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees